var data={"title":"Bosutinib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bosutinib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/521070?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bosutinib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bosutinib: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15367319\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bosulif</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24248798\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Bosulif</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965011\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, BCR-ABL Tyrosine Kinase Inhibitor;</li>\n      <li>\n        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034523\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Bosutinib is associated with a moderate emetic potential (Hesketh 2017; Roila 2016); nausea and vomiting may be managed with antiemetics and fluid replacement. In clinical studies of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), dose escalation in increments of 100 mg once daily (to a maximum of 600 mg once daily) was allowed in patients who did not achieve or maintain a hematologic, cytogenetic, or molecular response (in the absence of &ge; grade 3 adverse reactions).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ph+ CML, newly-diagnosed chronic phase:</b> Oral: 400 mg once daily; continue until disease progression or unacceptable toxicity (Cortes 2018)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ph+ CML, resistant or intolerant to prior therapy:</b> Oral: 500 mg once daily; continue until disease progression or unacceptable toxicity (Cortes 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed doses:</i> If a dose is missed beyond 12 hours, skip the dose and resume the usual dose the following day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034524\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034526\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Preexisting impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ph+ CML, newly diagnosed chronic phase:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CrCl &gt;50 to 80 mL/minute:</i> There are no dosage adjustments provided in manufacturer's labeling, however, based on the pharmacokinetics, exposure is not altered and the need for dosage adjustment is not likely.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CrCl 30 to 50 mL/minute:</i> Reduce dose to 300 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CrCl &lt;30 mL/minute:</i> Reduce dose to 200 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ph+ CML, resistant or intolerant to prior therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CrCl &gt;50 to 80 mL/minute:</i> There are no dosage adjustments provided in manufacturer's labeling, however, based on the pharmacokinetics, exposure is not altered and the need for dosage adjustment is not likely.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CrCl 30 to 50 mL/minute:</i> Reduce dose to 400 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CrCl &lt;30 mL/minute:</i> Reduce dose to 300 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal toxicity during treatment:</b> If unable to tolerate initial dose, reduce dose per adjustment recommendations for toxicity (withhold treatment until resolved, then consider resuming with the daily dose reduced by 100 mg; if clinically appropriate, may re-escalate dose to the starting dose).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemodialysis:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034527\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ph+ CML, newly diagnosed (chronic phase) or resistant/intolerant to prior therapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Preexisting impairment (mild, moderate, or severe):</b> Child-Pugh class A, B, or C: Reduce initial dose to 200 mg once daily (this dose is predicted to result in an AUC similar to that of patients with normal hepatic function; however, there is no efficacy data for this dose in CML patients with hepatic impairment).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatotoxicity during treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ALT or AST &gt;5 times ULN: Withhold treatment until recovery to &le;2.5 times ULN and resume at 400 mg once daily thereafter. If recovery to &le;2.5 times ULN takes &gt;4 weeks: Discontinue bosutinib.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ALT or AST &ge;3 times ULN in conjunction with bilirubin elevation &gt;2 times ULN and alkaline phosphatase &lt;2 times ULN: Discontinue bosutinib.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034525\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ph+ CML, newly diagnosed (chronic phase) or resistant/intolerant to prior therapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematologic toxicity:</b> ANC &lt;1,000/mm<sup>3</sup> or platelets &lt;50,000/mm<sup>3</sup>: Withhold treatment until ANC &ge;1,000/mm<sup>3</sup> <b>and</b> platelets &ge;50,000/mm<sup>3</sup>; if recovery occurs within 2 weeks, resume treatment at the same dose. If ANC and platelets remain low for &gt;2 weeks, upon recovery, resume treatment with the daily dose reduced by 100 mg. If cytopenia recurs, withhold until recovery and resume treatment with the daily dose reduced by an additional 100 mg. Doses &lt;300 mg daily have been used; however, efficacy has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nonhematologic toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Diarrhea:</i> Grade 3 or 4 (&ge;7 stools/day increase over baseline/pretreatment): Withhold treatment until recovery to &le; grade 1; may resume at 400 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Other clinically significant nonhematologic toxicity, moderate or severe:</i> Withhold treatment until resolved, then consider resuming with the daily dose reduced by 100 mg; may re-escalate dose to the starting dose if clinically appropriate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15367320\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bosulif: 100 mg, 400 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034461\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034528\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib is associated with a moderate emetic potential (Hesketh 2017; Roila 2016); nausea and vomiting may be managed with antiemetics and hydration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer with food. Swallow tablet whole; do not cut, crush or break.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104434\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14965013\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Chronic myelogenous leukemia:</b> Treatment of newly-diagnosed chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML); treatment of chronic, accelerated, or blast phase Ph+ CML in patients resistant or intolerant to prior therapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034460\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bosutinib may be confused with bortezomib, bosentan, brigatinib, dasatinib, imatinib, nilotinib, PONATinib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medical Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15236368\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (17% to 20%), chest pain (7% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (19% to 26%), headache (17% to 21%), dizziness (11% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (34% to 42%), pruritus (7% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypophosphatemia (50% [Gambacorti-Passerini 2014]), hypokalemia (18% [Gambacorti-Passerini 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (70% to 85%), nausea (35% to 48%), vomiting (18% to 43%), abdominal pain (25% to 42%), increased serum lipase (13% to 38% [Cortes 2012; Gambacorti-Passerini 2014]), decreased appetite (10% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (35% to 45%; grades 3/4: 14% to 39%), anemia (19% to 38%; grades 3/4: 11% to 27%), neutropenia (11% to 22%; grades 3/4: 7% to 20%), leukopenia (10% to 15%; grades 3/4: 4% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (18% to 31%), abnormal hepatic function tests (20% to 26%), increased serum AST (11% to 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (11% to 17%), weakness (10% to 13%), back pain (8% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal insufficiency (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Respiratory tract infection (10% to 39%), cough (22%), dyspnea (12% to 20%), nasopharyngitis (6% to 13%), pleural effusion (9% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (13% to 37%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension, pericardial effusion, prolonged Q-T interval on ECG</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Fluid retention (grade 3/4: 5%), dehydration, hyperkalemia, increased gamma-glutamyl transferase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia, gastritis, gastrointestinal hemorrhage, increased serum amylase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Febrile neutropenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatic injury, hepatic insufficiency, hepatotoxicity, increased serum bilirubin (grades &ge;3: 1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (3% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (6% to 10%), acute renal failure, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis, pneumonia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Genitourinary: Decreased estimated GFR (eGFR)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute pancreatitis, acute pulmonary edema, anaphylactic shock, erythema multiforme, exfoliative dermatitis, fixed drug eruption, granulocytopenia, hypersensitivity reaction, pericarditis, pulmonary hypertension, respiratory failure, Stevens-Johnson syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034466\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to bosutinib or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): History of long QT syndrome or with persistent QT interval &gt;480 milliseconds; uncorrected hypokalemia or hypomagnesemia; hepatic impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034474\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Anemia, neutropenia, and thrombocytopenia may occur. May require treatment interruption, dose reduction, or discontinuation. Monitor blood counts weekly during first month, then monthly thereafter (or as clinically indicated).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention/edema: Fluid retention, manifesting as pericardial effusion, pleural effusion, pulmonary edema and/or peripheral edema may occur; may be severe. Monitor for fluid retention (eg, weight gain) and manage appropriately; may require treatment interruption, dose reduction, or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicity: Diarrhea, nausea, vomiting, and abdominal pain may occur. Monitor; may require treatment interruption, dose reduction, discontinuation, or other management (eg, medications or fluids). For patients experiencing diarrhea (all grades), the median time to onset in patients with CML resistant or intolerant to prior therapy was 2 days; median duration (per event) was 2 days and the median number of diarrhea episodes per patient was 3 (range: 1 to 268); manage diarrhea with antidiarrheals and/or fluid replacement. Similarly, the median time to onset for diarrhea (all grades) in patients with newly-diagnosed CML was 3 days; the median duration per events was 3 days. Bosutinib is associated with a moderate emetic potential (Hesketh 2017; Roila 2016); nausea and vomiting may be managed with antiemetics and fluid replacement. GI hemorrhages have also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Serum transaminase (ALT and/or AST) elevations have been reported. In patients with transaminase elevation, ~80% developed the transaminase elevation within the first 3 months of therapy. In a clinical study in patients with newly-diagnosed chronic phase CML, the median time to onset of elevated ALT and AST was 32 and 43 days, respectively; the median duration was 20 and 15 days, respectively. In patients with CML resistant or intolerant to prior therapy, the mediation time to onset of ALT and AST elevation was 35 and 33 days, respectively, and the median duration (for each) was 21 days. One case of drug-induced liver injury has been reported in a breast cancer clinical trial (not an approved indication); full recovery occurred after discontinuation. Monitor transaminases monthly for the first 3 months (and as clinically indicated; monitor more frequently if elevations occur). May require therapy interruption, dosage reduction, or therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions have been reported, including anaphylaxis and anaphylactic shock (rare).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Acute pancreatitis has been reported (rare); use caution in patients with a prior history of pancreatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: QTcF &gt;500 milliseconds was observed rarely in clinical trials (Cortes 2012); patients with significant or uncontrolled cardiovascular disease (including prolonged QT interval at baseline) were not studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: Declines in glomerular filtration rates throughout bosutinib treatment have been observed in clinical studies; monitor renal function at baseline and during therapy, particularly in patients with preexisting impairment or other risk factors for renal dysfunction. Consider dosage adjustment in patients with renal dysfunction at baseline or with treatment emergent impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Bosutinib exposure is increased in patients with hepatic impairment; dose reduction is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Bosutinib exposure is increased in patients with moderate or severe renal impairment. Consider dosage adjustment in patients with renal dysfunction at baseline or with treatment emergent impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal medications: Proton pump inhibitors (PPIs) may decrease bosutinib effects; consider using short acting antacids or H<sub>2</sub> antagonists instead of PPIs. Separate administration of antacids or H<sub>2</sub> antagonists from bosutinib by at least 2 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15255889\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15255887\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=86371&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Bosutinib. Management: Administer antacids more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bitter Orange: May increase the serum concentration of Bosutinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Bosutinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Bosutinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Bosutinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Bosutinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May decrease the serum concentration of Bosutinib. Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomegranate: May increase the serum concentration of Bosutinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the serum concentration of Bosutinib. Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Bosutinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Star Fruit: May increase the serum concentration of Bosutinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034495\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice may increase bosutinib plasma concentration. Management: Avoid grapefruit juice during bosutinib therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034463\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on data from animal reproduction studies and the mechanism of action, bosutinib may cause fetal harm if administered in pregnancy. Verify pregnancy status in females of reproductive potential prior to initiating therapy. Females of reproductive potential should use effective contraception during bosutinib treatment and for at least 1 month after the last bosutinib dose. Bosutinib may impair fertility in males and females of reproductive potential (based on findings in animal studies).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034465\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if bosutinib is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for at least 1 month after the last bosutinib dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034531\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets (weekly during first month, then monthly thereafter, or as clinically indicated); hepatic enzymes (monthly for first 3 months and as clinically indicated; monitor more frequently with transaminase elevations); renal function (at baseline and throughout therapy); pregnancy test (prior to treatment initiation in females of reproductive potential); diarrhea episodes; fluid/edema status (eg, weight gain). Monitor adherence.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034498\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Bosutinib is a BCR-ABL tyrosine kinase inhibitor (TKI); inhibits BCR-ABL kinase that promotes CML. Also inhibits SRC family (including SRC, LYN, and HCK). Bosutinib has minimal activity against c-KIT and platelet-derived growth factor receptor (PDGFR), which are nonspecific targets associated with toxicity in other TKIs (Cortes 2012). Bosutinib has activity in 16 of 18 imatinib-resistant BCR-ABL mutations, with the exceptions of the T315I and V299L mutants (Cortes 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15034500\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Median time to complete hematologic response (in responders): 2 weeks (Cortes 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Median time to major cytogenetic response (in responders): 12.3 weeks (Cortes 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Median time to first complete cytogenic response: 12.9 weeks (Cortes 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Slow (Abbas 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 6,080 &plusmn; 1,230 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 94% to plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4, primarily to inactive metabolites oxydechlorinated (M2) bosutinib and <i>N</i>-desmethylated (M5) bosutinib, also to bosutinib <i>N</i>-oxide (M6)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 34% when administered with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 22 to 27 hours (Cortes 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (~91%); urine (~3%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570453\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Bosulif Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (120): $17,058.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (30): $17,058.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (30): $17,058.98</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23671833\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bosulif (AT, AU, BB, BE, CH, CZ, DE, DK, ES, FR, GB, HR, HU, IE, IL, IS, JP, LT, LU, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR);</li>\n      <li>Busulif (EE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abbas R, Chalon S, Leister C , El Gaaloul M, Sonnichsen D, Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. <i>Cancer Chemother Pharmacol</i>. 2013;71(1):123-132.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/23053269/pubmed\" target=\"_blank\" id=\"23053269\">23053269</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Abbas R, Hug BA, Leister C, et al, &ldquo;A Phase I Ascending Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Bosutinib (SKI-606) in Healthy Adult Subjects,&rdquo; <i>Cancer Chemother Pharmacol</i>, 2012, 69(1):221-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/21691746/pubmed\" target=\"_blank\" id=\"21691746\">21691746</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bosulif (bosutinib) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. <i>J Clin Oncol. </i>2018;36(3):231-237. doi: 10.1200/JCO.2017.74.7162.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/29091516/pubmed\" target=\"_blank\" id=\"29091516\">29091516</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortes JE, Kantarjian HM, Br&uuml;mmendorf TH, et al, &ldquo;Safety and Efficacy of Bosutinib (SKI-606) in Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Imatinib,&rdquo; <i>Blood</i>, 2011, 118(17):4567-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/21865346/pubmed\" target=\"_blank\" id=\"21865346\">21865346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. <i>J Clin Oncol</i>. 2012;30(28):3486-3492.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/22949154/pubmed\" target=\"_blank\" id=\"22949154\">22949154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24944159\"></a>Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. <i>Am J Hematol</i>. 2014;89(10):947-953.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/24944159/pubmed\" target=\"_blank\" id=\"24944159\">24944159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khoury HJ, Cortes JE, Kantarjian HM, et al, &ldquo;Bosutinib is Active in Chronic Phase Chronic Myeloid Leukemia After Imatinib and Dasatinib and/or Nilotinib Therapy Failure,&rdquo; <i>Blood</i>, 2012, 119(15):3403-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/22371878/pubmed\" target=\"_blank\" id=\"22371878\">22371878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Redaelli S, Piazza R, Rostagno R, et al, &ldquo;Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants,&rdquo; <i>J Clin Oncol</i>, 2009, 27(3):469-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/19075254/pubmed\" target=\"_blank\" id=\"19075254\">19075254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bosutinib-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 86371 Version 134.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F15367319\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F24248798\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F14965011\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F15034523\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F15034524\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15034526\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15034527\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F15034525\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F15367320\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F15034461\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F15034528\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104434\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F14965013\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F15034460\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F15236368\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F15034466\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F15034474\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F15255889\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F15255887\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F15034495\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F15034463\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F15034465\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15034531\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F15034498\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F15034500\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570453\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23671833\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/86371|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bosutinib-patient-drug-information\" class=\"drug drug_patient\">Bosutinib: Patient drug information \t</a></li></ul></div></div>","javascript":null}